Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling

Folia Histochemica et Cytobiologica

Volumn 47, Issue 3, 2009, Pages 485-489

  Lukasiewicz, Ewa ^a   Miekus, Katarzyna ^a   Kijowski, Jacek ^a   Drabik, Grazyna ^a   Wilusz, Miroslawa ^a   Bobis Wozowicz, Sylwia ^a   Majka, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Bone marrow; Homing; Invasion; MET receptor; Metastasis; Rhabdomyosarcoma

Indexed keywords

SCATTER FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE; XENOGRAFT;

EID: 77149136087     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0108-x     Document Type: Article

References (24)

1. Parham DM, Barr FG. Skeletal muscle tumors. In: Fletcher CDM, Unni KK, Mertens F, ed. Pathology and genetics of tumors of soft tissue sarcoma. Lion: IARC press; 2002, pp. 141-154.
2. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3:113-117.
3. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869-2872.
4. Galili N, Davis RJ, Fredericks WJ et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5:230-235.
5. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997;19:483-491.
6. Sorensen PH, Lynch JC, Qualman SJ et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679.
7. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Upregulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 1998;58:3542-3546.
8. Lesko E, Majka M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci. 2008;13:1271-1280.
9. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29: 209-248.
10. Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081-2088.
11. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene. 1997;14:2417-2423.
12. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347-361.
13. Jeffers M, Rong S, Anver M, Vande Woude GF. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene. 1996;13:853-856.
14. Nishimura K, Matsumiya K, Miura H et al. Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells. Int J Androl. 2003;26:175-179.
15. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol. 2003; 14:3047-3060.
16. Hiscox S, Jiang WG. Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor. Biochem Biophys Res Commun. 1997;233:1-5.
17. Mine S, Fujisaki T, Kawahara C et al. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp Cell Res. 2003;288:189-197.
18. Trusolino L, Cavassa S, Angelini P et al. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J. 2000;14:1629-1640.
19. Kawakami-Kimura N, Narita T, Ohmori K et al. Involvement of hepatocyte growth factor in increased integrin expression on HepG2 cells triggered by adhesion to endothelial cells. Br J Cancer. 1997;75:47-53.
20. Sharp R, Recio JA, Jhappan C et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med. 2002 8:1276-1280.
21. Jankowski K, Kucia M, Wysoczynski M, Reca R et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003;63:7926-7935.
22. Taulli R, Scuoppo C, Bersani F et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 2006;66:4742-4749.
23. Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomysoracoma cells in vitro and seeding into bone marrow in vivo. Anti-Cancer Drugs. 2007;18:1173-1181.
24. Rees H, Williamson D, Papanastasiou A et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors. 2006;24: 197-208.